Vicenzi et al. demonstrated that, in COVID-19 patients, treatment with the MR antagonist canrenone had an overall positive impact on all-cause mortality and clinical improvement, most probably via a direct anti-inflammatory effect [32]. The gene discussed is NR3C2; the disease is COVID-19.